[DS8201-A-U207] A phase 2, multicenter, randomized study of trastuzumab deruxtecan in subjects with HER2-overexpressing locally advanced, unresectable or metastatic colorectal cancer (Destiny-CRC02)

Administered By

Awarded By

Contributors

Start/End

  • April 22, 2021 - May 9, 2026